Scynexis Inc

SCYXNASDAQ · USD
4.84USD0.00 (+2.98%)
557

Scynexis Inc (SCYX) Covered Calls

As of September 11, 2026, SCYX has 4 covered call opportunities in the coming three months. Return ranges from 5.4 to 70.5% until expiration. Annualized return ranges from 10.4 to 136.1%. The nearest expiration is October 16, 2026. Maximum potential profit is $341.

Read more

Running SCYX covered calls helps you generate consistent income from Scynexis Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Scynexis Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best SCYX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if SCYX stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling SCYX covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Scynexis Inc covered call is worth writing.

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp.

The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Income-focused investors, long-term SCYX holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling SCYX covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Scynexis Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryDrug Manufacturers - Specialty & Generic
  • SectorHealthcare
  • IV percentile67.86% Elevated
  • Market cap (M$)48
  • 52 weeks high-53.82%
  • 52 weeks low37.11%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$36.55
    655.17% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-04
  • P/E
  • Future P/E
  • EPS (ttm)-1.84
  • EPS growth next 5 years-15.40%

As of September 11, 2026

2027-03-191897.5054.960.751.40341.0070.45136.06-15.50+0.50460.65
2026-12-18985.003.311.002.00116.0023.9789.26-20.66+0.65191.00
2026-10-16355.003.310.153.9031.006.4066.79-3.10+0.7003.75
2027-03-191895.003.310.104.9026.005.3710.37-2.07+0.7624.80

As of September 11, 2026

Sell covered calls with the data behind you

Find the best SCYX covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial